Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical- stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's d ...

Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership role ...

Key Takeaways NVO launched the once-daily Wegovy pill in the U.S., the first-ever GLP-1 obesity treatment in oral form.NVO sees the pill as a way to regain lost market share after injectable Wegovy sales slowed in 2025.NVO's tiered pricing and broad rollout strategy aim to curb compounded use and lift Wegovy sales in 2026.Shares of Novo Nordisk (NVO) jumped 5.2% on Monday and about 4% in the pre-market hours today as investors cheered the U.S. launch of its newly approved Wegovy pill (once-daily oral semagl ...

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 44 Annual J.P. Morgan Healthcare Conference. The conference will take place January 12- 15, 2026, in San Francisco, California. Details are as follows: About Viking Therapeutics ...

Key Takeaways NVO won FDA approval for oral Wegovy, the first GLP-1 RA pill for weight management and CV risk reduction.NVO's oral Wegovy matched injectable efficacy with similar safety and easier dosing that may boost adherence.First-mover oral launch could help NVO regain share from LLY and boost Wegovy sales after 2025 slowdown.Last month, Novo Nordisk (NVO) announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the ...

Core Insights - Viking Therapeutics (VKTX) is advancing its late-stage obesity candidate VK2735, a dual GLP-1 and GIP receptor agonist, through multiple clinical studies for obesity treatment [1][2] Group 1: Clinical Development - VKTX is conducting two late-stage studies, VANQUISH-1 and VANQUISH-2, evaluating the SC version of VK2735 over a 78-week treatment period [2] - Enrollment in the VANQUISH-1 study has been completed with approximately 4,650 patients, exceeding the target of 4,500 patients, while nearly 1,100 patients are expected to be enrolled in VANQUISH-2 by the end of this quarter [3][11] Group 2: Market Dynamics - The rapid enrollment in VKTX's studies indicates strong demand for VK2735, reflecting high patient and physician enthusiasm, which could lead to significant commercial potential if the drug proves effective [4] - The obesity market in the U.S. is projected to reach $100 billion by 2030, with Eli Lilly and Novo Nordisk already generating substantial revenue from their obesity drugs [5] Group 3: Competitive Landscape - Novo Nordisk has received FDA approval for the oral version of Wegovy, enhancing patient adherence due to its convenience, while Eli Lilly is pursuing approval for its oral candidate, orforglipron [6][7] - Both companies are investing in next-generation obesity therapies, with Eli Lilly developing retatrutide and Novo Nordisk advancing amycretin, indicating a competitive landscape that is evolving rapidly [8][9] Group 4: Financial Performance - VKTX shares have underperformed the industry over the past year, trading at a premium with a price-to-book value (P/B) ratio of 5.58 compared to the industry average of 3.61 [12][14] - Estimates for VKTX's loss per share for 2025 and 2026 have widened recently, indicating potential challenges ahead [16]

Key Points Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges. 10 stocks we like better than Viking Therapeutics › One great way to earn above-average market returns is to identify stocks that aren't performing well -- even as broader equities are moving higher -- but could eventually rebound. There are plenty of candidates to pick from as the stock market closes out another solid year. Two beaten-down stocks worth considering for ...

Viking Therapeutics (VKTX) may be flying under the radar, but it could soon become one of the most closely watched biotech stories heading into 2026. It is a high-risk, high-reward biotech company trying to build the next generation of obesity treatments. Over the past year, the company has made significant strides in advancing its lead obesity treatment, VK2735, while strengthening its clinical pipeline and positioning its balance sheet to support multiple future catalysts. Let’s find out if it is a goo ...

Key Takeaways NVO's Wegovy pill becomes the first oral GLP-1 for obesity and plans a U.S. launch in early January 2026.FDA approved NVO's once-daily oral Wegovy to cut excess weight, maintain loss and reduce cardiovascular risk.Novo Nordisk's OASIS 4 study showed 16.6% mean weight loss, with one in three patients losing 20% or more.Novo Nordisk (NVO) announced the FDA approval of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and ...

Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. oatautta/Shutterstock.com Pantginis maintains a long-term view based on the company’s differentiated VK2735 oral and injectable formulations. This view come ...